American Federation for Medical Research

Back to 2019 Abstracts


Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 is Associated with Subclinical Coronary Artery Diseases in Psoriasis
Amit K. Dey1, Ranjitha Gaddipati2, Youssef Elnabawi1, Emily Ongstad2, Aditya Goyal1, Justin Rodante1, Aparna Sajja1, Alexander Sorokin1, Heather Teague1, Aarthi Reddy1, Milena Aksentijevich1, Noor Khalil1, Jenis Argueta-Amaya1, Harry Choi1, Parag Shukla1, Yvonne Baumer1, Aditya Joshi1, Veit Sandfort1, Martin Playford1, Marcus Chen1, David Bluemke4, Sotirios Karathanasis2, Joel Gelfand3, Ruchi Gupta2, Nehal N. Mehta1. 1Cardiology, NHLBI, NIH, Bethesda, Maryland, United States, 2Medimmune, Gaithersburg, Maryland, United States, 3University of Pennsylvania, PHILADELPHIA, Pennsylvania, United States, 4Univeristy of Wisconsin, Madison, Wisconsin, United States

Purpose of Study Psoriasis (PSO), a chronic inflammatory skin disease is associated with increased non-calcified coronary plaque burden (NCB) as well as heightened MI. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), a scavenger receptor for oxidized LDL, is critical in the development of NCB. We sought to understand the relationship of circulating soluble LOX-1 (sLOX-1) with NCB in psoriasis.
Methods Used Consecutive psoriasis patients (n=175) and healthy controls (n=30) underwent coronary CT angiography (CCTA) scans to quantify NCB (QAngio, Medis). Circulating sLOX-1 was measured by ELISA (Medimmune, USA).
Summary of Results Psoriasis patients were middle-aged, predominantly male, with low CV risk by Framingham risk and had moderate-severe psoriasis severity (Table 1). sLOX-1 was elevated in psoriasis and associated with psoriasis severity (β =0.24, p=0.002) as well as NCB (β =0.08, p=0.037). Patients with improvement in psoriasis severity at one-year had a concomitant reduction in sLOX-1, which was associated with a reduction in NCB (β =0.12, p=0.04). Finally, early reduction in sLOX-1 following biologic psoriasis therapy associated with a late reduction in NCB at 1-year beyond traditional risk factors (β=0.41, p=0.048).
Conclusions sLOX-1 was associated with NCB in psoriasis. Furthermore, improvement in circulating sLOX-1 following biologic psoriasis treatment was associated with reduction in NCB. Randomized controlled trials are needed to test the effect of biologic therapy on sLOX-1.


Back to 2019 Abstracts